On Monday, Incyte Corporation (NASDAQ:INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 ...

William Blair analysts led by Matt Phipps, who rate Incyte at Outperform, called the news disappointing. They highlighted ...

Analyst Evan Seigerman from BMO Capital reiterated a Sell rating on Incyte (INCY – Research Report) and increased the price target to $52.00 ...

U.S. stocks are drifting in mixed trading after clawing back losses from earlier in the morning. The S&P 500 was virtually ...